DiaCarta, a technology-driven translational genomics and molecular diagnostics company located in
QClamp™ is a revolutionary new way to screen for somatic mutations, which utilizes a sequence specific wild-type template Xeno-nucleic acid "Molecular Clamp" (XNA) that suppresses PCR amplification of wild-type template DNA and allows selective PCR amplification of only mutant templates. This allows the detection of mutant DNA despite a large excess of wild-type template from any sample, including FFPE and whole blood.
The QClamp™ technology is particularly suited to “liquid biopsy” applications for the detection of tumor-derived, cell-free DNA in plasma or urine, which can achieve sensitivities equivalent or even better than droplet digital PCR (ddPCR). Utilizing only standard qPCR real-time instrumentation, QClamp™ Real-Time PCR mutation tests are highly sensitive and can detect mutated DNA even when the concentration is below 0.1%.
"The problem with sequencing technology right now, if you take a tumor sample, it's like a big haystack with a few needles in it,” Dr.
“Recent studies have demonstrated that DNA sequencing is one of the least sensitive methods for characterizing mutation with only 10-20% of mutated DNA detected.” DiaCarta CEO and Founder Dr.
DiaCarta, based in
For more information, please visit DiaCarta website at http://www.diacarta.com, or call at +1 (510) 3148858.
Read the full story at http://www.prweb.com/releases/2014/02/prweb11618720.htm
Most Popular Stories
- Ukraine Crisis Limits Losses in Gold, Silver
- Can GOP Dodge Immigration Bullet?
- Software Writers Sought in Indiana
- Chiquita, Fyffes to Form Top Banana
- Photo ID Required for Unemployment Benefits
- Big Earthquake Rumbles Northern California
- China's Money Rate Drops on Slowdown Concern
- Mt. Gox Files for Bankruptcy in U.S.
- Tech Firms to Increase Hiring for 4th Year in a Row
- '300' Sequel Conquers Box Office Foes